10 December 2021
Medannex today announced the latest data on their new targeted agent, MDX-124, demonstrating significant anti-cancer activity in several preclinical models of triple-negative breast cancer. In addition to its efficacy as a single agent, MDX-124 significantly enhances the activity of various long-established anti-cancer drugs that form the backbone of many treatment regimens.
MDX-124, the first monoclonal antibody to target annexin-A1, has previously been shown to significantly reduce cancer cell proliferation and migration, as well as activating immune cells to destroy cancer cells.
The newly-published data reveal a profound synergy when MDX-124 is used in combination with common chemotherapies including cisplatin and paclitaxel, resulting in significantly greater cancer cell death.
Furthermore, in vivo, Medannex’s molecule was shown to markedly potentiate the impact of anti-PD-1 immunotherapy, another widely-used class of cancer treatment.
Professor Daniel Palmer, of the University of Liverpool’s Department of Molecular and Clinical Cancer Medicine, commented: ‘These non-clinical data show great potential for MDX-124 to improve treatment outcomes for patients in a range of clinically-challenging tumour types.’
Medannex CEO Ian Abercrombie said: ‘We are very excited by the powerful synergy between our molecule and well established cancer therapies. This could significantly improve patient outcomes, not only in terms of treatment response but also by reducing dosing and side effects. We will build these combinations into our modular approach to our First-in-Human study, which will commence early in 2022.’
The new data, generated by Medannex in collaboration with Anglia Ruskin University (Cambridge) and Brighton & Sussex Medical School, were unveiled at the San Antonio Breast Cancer Symposium (Texas, USA).